Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape.
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 10, 11, 1, 27, 8 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Attention Deficit Hyperactivity Disorder (ADHD) - Overview
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
3Z ehf
4P-Pharma SAS
ABVC BioPharma Inc
AgoneX Biopharmaceuticals Inc
Altus Formulation Inc
Amarantus Bioscience Holdings Inc
Arbor Pharmaceuticals LLC
Attentive Therapeutics Inc
Avekshan LLC
BCWorld Pharm Co Ltd
Cennerv Pharma (S) Pte Ltd
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Commave Therapeutics SA
Curemark LLC
DD Therapeutics LLC
DURECT Corp
Eli Lilly and Co
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Highland Therapeutics Inc
Hyloris Pharmaceuticals SA
INVENT Pharmaceuticals Inc
Kashiv BioSciences LLC
KemPharm Inc
Lennham Pharmaceuticals Inc
M et P Pharma AG
Marvel Biotechnology Inc
MD Healthcare Inc
Mind Medicine MindMed Inc
Mindset Pharma Inc
NeuroNascent Inc
NLS Pharmaceutics AG
Nobias Therapeutics Inc
NutriBand Inc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
P2D Inc
PolyCore Therapeutics LLC
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Shenox Pharmaceuticals LLC
Shionogi & Co Ltd
SK Biopharmaceuticals Co Ltd
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Taho Pharmaceuticals Ltd
Tonix Pharmaceuticals Holding Corp
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Yichang Renfu Pharmaceutical Co Ltd
Yuyu Pharma Inc
Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles
(methylphenidate hydrochloride + cyproheptadine) ER - Drug Profile
Product Description
Mechanism Of Action
(methylphenidate hydrochloride + naltrexone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
3Z-20001 - Drug Profile
Product Description
Mechanism Of Action
3Z-20002 - Drug Profile
Product Description
Mechanism Of Action
3Z-20003 - Drug Profile
Product Description
Mechanism Of Action
3Z-20004 - Drug Profile
Product Description
Mechanism Of Action
4P-003 - Drug Profile
Product Description
Mechanism Of Action
ABV-1505 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AFI-002 - Drug Profile
Product Description
Mechanism Of Action
amfetamine ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
AR-19 - Drug Profile
Product Description
Mechanism Of Action
History of Events
atomoxetine - Drug Profile
Product Description
Mechanism Of Action
atomoxetine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
BCWPE-003 - Drug Profile
Product Description
Mechanism Of Action
brilaroxazine - Drug Profile
Product Description
Mechanism Of Action
History of Events
CB-8411 - Drug Profile
Product Description
Mechanism Of Action
centanafadine SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-4612 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CX-717 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dexmethylphenidate hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
dextroamphetamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
dextroamphetamine MR - Drug Profile
Product Description
Mechanism Of Action
History of Events
dopamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug for Attention Deficit Hyperactivity Disorder and Obesity - Drug Profile
Product Description
Mechanism Of Action
Drugs for Attention Deficit Hyperactivity Disorder and Lymphatic Anomalies - Drug Profile
Product Description
Mechanism Of Action
Drugs for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
edivoxetine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
eltoprazine - Drug Profile
Product Description
Mechanism Of Action
History of Events
histamine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
INV-400 - Drug Profile
Product Description
Mechanism Of Action
JJC-8091 - Drug Profile
Product Description
Mechanism Of Action
History of Events
K-129 - Drug Profile
Product Description
Mechanism Of Action
KP-484 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-922 - Drug Profile
Product Description
Mechanism Of Action
KR-33028 - Drug Profile
Product Description
Mechanism Of Action
levofacetoperane - Drug Profile
Product Description
Mechanism Of Action
History of Events
lisdexamphetamine dimesylate - Drug Profile
Product Description
Mechanism Of Action
lysergic acid diethylamide - Drug Profile
Product Description
Mechanism Of Action
History of Events
mazindol CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-204 - Drug Profile
Product Description
Mechanism Of Action
MDH-001 - Drug Profile
Product Description
Mechanism Of Action
MDH-204 - Drug Profile
Product Description
Mechanism Of Action
methylphenidate - Drug Profile
Product Description
Mechanism Of Action
methylphenidate ER - Drug Profile
Product Description
Mechanism Of Action
methylphenidate hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
methylphenidate hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
methylphenidate IR - Drug Profile
Product Description
Mechanism Of Action
NLS-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NLS-8 - Drug Profile
Product Description
Mechanism Of Action
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
PCT-3012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PD-3044 - Drug Profile
Product Description
Mechanism Of Action
PF-8001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-8026 - Drug Profile
Product Description
Mechanism Of Action
History of Events
S-874713 - Drug Profile
Product Description
Mechanism Of Action
SHX-009 - Drug Profile
Product Description
Mechanism Of Action
SKL-13865 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize ADORA for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize 5-HT2A for Alzheimer's Disease and Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit SLC9A9 for ADHD - Drug Profile
Product Description
Mechanism Of Action
SPN-443 - Drug Profile
Product Description
Mechanism Of Action
SPN-446 - Drug Profile
Product Description
Mechanism Of Action
TNX-1600 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRN-110 - Drug Profile
Product Description
Mechanism Of Action
TRN-148 - Drug Profile
Product Description
Mechanism Of Action
TRN-176 - Drug Profile
Product Description
Mechanism Of Action
vafidemstat - Drug Profile
Product Description
Mechanism Of Action
History of Events
viloxazine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
VU-0238429 - Drug Profile
Product Description
Mechanism Of Action
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
Featured News & Press Releases
Feb 02, 2022: ABVC BioPharma announces principal investigator meeting for phase II part 2 ADHD clinical study
Dec 17, 2021: MindMed initiates phase 2a LSD trial for the treatment of adult ADHD
Nov 17, 2021: OWP Pharmaceuticals announces IND authorization for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of attention deficit hyperactivity disorder
Nov 05, 2021: Tris Pharma announces FDA approval of DYANAVEL XR (amphetamine) once-daily extended-release oral tablets, CII, for ADHD
Oct 27, 2021: Central IRB approved for ABV-1505 phase II part II in Taiwan sites
Sep 13, 2021: ABVC BioPharma completes site selection for ABV-1505 ADHD phase II part 2 clinical study
Sep 02, 2021: Supernus announces Qelbree sNDA for adult indication accepted for review by FDA
Sep 01, 2021: ABVC BioPharma announces new PCT filings for MDD and ADHD treatments
Aug 05, 2021: Marvel Biosciences updates market on its lead caffeine inspired asset MB-204 for neurological diseases
Jul 22, 2021: Methylphenidate - use in pregnancy
May 24, 2021: Qelbree (viloxazine extended-release capsules), a new non-controlled substance, now available for the treatment of ADHD in pediatric patients 6-17 years of age
May 05, 2021: NLS Pharmaceutics announces patent issuance in Europe for its mazindol controlled-release formulation (mazindol CR)
Apr 22, 2021: OWP Pharmaceuticals announces patent application for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of Attention Deficit Hyperactivity Disorder
Apr 02, 2021: Supernus announces FDA approval of Qelbree (SPN-812) for the treatment of ADHD
Feb 22, 2021: Supernus receives FDA notice assigning early April 2021 PDUFA date for SPN-812 NDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 3Z ehf, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by ABVC BioPharma Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by AgoneX Biopharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Altus Formulation Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Attentive Therapeutics Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Avekshan LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cennerv Pharma (S) Pte Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Commave Therapeutics SA, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DD Therapeutics LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Co, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by EncepHeal Therapeutics Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hyloris Pharmaceuticals SA, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Kashiv BioSciences LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Lennham Pharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by M et P Pharma AG, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Marvel Biotechnology Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by MD Healthcare Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mind Medicine MindMed Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mindset Pharma Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroNascent Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharmaceutics AG, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Nobias Therapeutics Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NutriBand Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Oryzon Genomics SA, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by OWP Pharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by PolyCore Therapeutics LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by RespireRx Pharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shenox Pharmaceuticals LLC, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shionogi & Co Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Suven Life Sciences Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taho Pharmaceuticals Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vallon Pharmaceuticals Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Yuyu Pharma Inc, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..1)
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..2)
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..3)
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..4)
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
